Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Vericiguat is an oral soluble guanylate cyclase stimulator. Its effect in patients with heart failure and reduced ejection fraction who had recently been hospitalized...
Vericiguat is an oral soluble guanylate cyclase stimulator. Its effect in patients with heart failure and reduced ejection fraction who had recently been hospitalized...
Individuals with cardiovascular disease are more sensitive to influenza-related complications and adverse clinical outcomes. These individuals have a less vigorous immune response to standard-dose...
Hyperuricemia is a known risk factor for chronic kidney disease (CKD). However, the risk of CKD in subjects with hypouricemia remains controversial. The author...
Hypertension is an essential risk factor for morbidity and mortality in patients with CKD. There is less knowledge to suggest, whether Ambulatory BP Monitoring...
Recently there is a substantial increase in the public health burden of diabetes and chronic kidney disease (CKD). Due to continuous research and trials,...
To line up with their mission of reducing the global burden of high blood pressure (BP), the International Society of Hypertension (ISH) has put...